Updated Data Announced for ReCor's Paradise Renal Denervation System

April 9, 2012—ReCor Medical (Ronkonkoma, NY) announced updated data from the REDUCE first-in-man clinical study of the company's Paradise percutaneous renal denervation system.

The new data show that systolic blood pressure was reduced by a statistically significant average of 36 mm Hg in eight patients at 90-days follow-up. As the company noted, the scientific literature demonstrates that a 5 mm Hg reduction in blood pressure results in a 14% decrease in stroke, a 9% decrease in heart disease, and a 7% decrease in mortality.

According to ReCor, Thomas A. Mabin, MD, first reported the preliminary first-in-man clinical data at the TREND 2012 transcatheter renal denervation scientific meeting in Frankfurt, Germany, showing that systolic blood pressure was reduced by an average of 31 mm Hg in seven patients at 60-day follow-up after treatment with Paradise.

Paradise is an ultrasound platform for achieving renal denervation in patients with treatment-resistant hypertension. The device earned CE Mark approval in February, as reported by Cardiac Interventions Today.

The Paradise system includes a 6-F–compatible catheter with a cylindrical transducer that, according to the company, emits ultrasound energy circumferentially, allowing for a rapid and highly efficient renal denervation procedure. The device is able to uniformly denervate all the way around the arterial wall and simultaneously cool the endothelium to help enable a safe, consistent, and fast renal denervation procedure, stated ReCor Medical.